In vitro evaluation of voriconazole against some clinically important fungi

Antimicrobial Agents and Chemotherapy

Volumn 41, Issue 8, 1997, Pages 1832-1834

  McGinnis, Michael R ^a   Pasarell, Lester ^a   Sutton, Deanna A ^b   Fothergill, Annette W ^b   Cooper Jr , Chester R ^a   Rinaldi, Michael G ^b,c  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; ITRACONAZOLE; VORICONAZOLE;

ARTICLE; ASCOMYCETES; BLASTOMYCES DERMATITIDIS; COCCIDIOIDES IMMITIS; CONTROLLED STUDY; DRUG SENSITIVITY; FUNGUS; HISTOPLASMA CAPSULATUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PARACOCCIDIOIDES BRASILIENSIS; PENICILLIUM MARNEFFEI; PRIORITY JOURNAL; SPOROTHRIX SCHENCKII; TRICHOSPORON BEIGELII;

EID: 0030744632     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.41.8.1832     Document Type: Article

References (26)

1. Barchiesi, F., M. Restrepo, D. A. McGough, and M. G. Rinaldi. 1995. In vitro activity of a new antifungal triazole: UK-109,496, abstr. F71, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
2. Barry, A. L., and S. D. Brown. 1996. In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species. Antimicrob. Agents Chemother. 40:1948-1949.
3. Denning, D., A. del Favero, E. Gluckman, D. Norfolk, M. Ruhnke, S. Yonren, P. Troke, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in acute invasive aspergillosis, abstr. F80, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
4. Dupont, B., D. Denning, H. Lode, S. Yonren, P. Troke, and N. Sarantris. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: clinical efficacy in chronic invasive aspergillosis, abstr. F81, p. 127. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
5. Espinel-Ingroff, A. 1996. Evaluation of the in vitro activity of the new triazole voriconazole against opportunistic filamentous fungi, abstr. F84, p. 114. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
6. Espinel-Ingroff, A., and T. Flynn. 1996. Antifungal activity of the new triazole voriconazole against established, new and emerging yeast pathogens: a comparative study, abstr. F83, p. 114. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. George, D., P. Miniter, and V. T. Andriole. 1996. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob. Agents Chemother. 40:86-91.
8. Hitchcock, C. A., R. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Aspergillus, abstr. F74, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Hitchcock, C. A., R. J. Andrews, B. G. H. Lewis, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity in experimental infections with Cryptococcus, abstr. F75, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Hitchcock, C. A., G. W. Pye, G. P. Oliver, and P. F. Troke. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: antifungal activity and selectivity in vitro, abstr. F72, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
11. Jezequel, S. G., M. Clark, S. Cole, K. E. Evans, and P. Wastall. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pre-clinical pharmacokinetics, abstr. F76, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
12. Jezequel, S. G., M. Clark, K. Evans, S. Roffey, P. Wastall, and R. Webster. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in animals, abstr. F77, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
13. Martin, M. V., J. Yeats, and C. A. Hitchcock. 1997. Comparison of voriconazole (UK-109,496) and itraconazole in prevention and treatment of Aspergillus fumigatus endocarditis in guinea pigs. Antimicrob. Agents Chemother. 41:13-16.
14. McGinnis, M. R., L. Pasarell, and C. R. Cooper, Jr. 1995. In vitro susceptibility of clinical mould isolates to UK-109,496, amphotericin B, fluconazole, and itraconazole, abstr. E76, p. 99. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. McGinnis, M. R., and M. G. Rinaldi. 1996. Antifungal drugs: mechanisms of action, drug resistance, susceptibility testing, and assays of activity in biologic fluids, p. 176-211. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins, Co., Baltimore, Md.
16. Murphy, M., E. M. Bernard, T. Ishimaru, and D. Armstrong. 1997. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 41:696-698.
17. National Committee for Clinical Laboratory Standards. 1995. Reference method for broth dilution antifungal susceptibility testing of yeasts. Tentative standard M27-T. National Committee for Clinical Laboratory Standards, Villanova, Pa.
18. Patterson, B. E., and P. E. Coates. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: pharmacokinetics in man, abstr. F78, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
19. Patterson, B. E., S. Roffey, S. G. Jezequel, and B. Jones. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: disposition in man, abstr. F79, p. 126. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
20. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent, against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
21. Rex, J. H., M. A. Pfaller, J. N. Galgiani, M. S. Bartlett, A. Espinel-Ingroff, M. A. Ghannaum, M. Lancaster, F. C. Odds, M. G. Rinaldi, T. J. Walsh, and A. L. Barry. 1997. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Clin. Infect. Dis. 24:235-247.
22. Richardson, K., A. S. Bell, R. P. Dickinson, S. Narayanaswami, and S. J. Ray. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: synthesis and SAR, abstr. F69, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
23. Sanati, H., P. H. Belanger, R. A. Fratti, and M. A. Ghannoum. 1996. Effect of voriconazole (UK-109,496) on the sterol biosynthesis of Candida albicans and Candida krusei, abstr. C65, p. 46. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
24. Sutton, D. A., A. W. Fothergill, F. J. Barchiesi, and M. G. Rinaldi. 1996. In vitro activity of voriconazole against dimorphic fungi, abstr. F85, p. 114. In Abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
25. Troke, P. F., A. S. Bell, R. P. Dickinson, C. A. Hitchcock, S. Jezequel, S. Narayanaswami, S. J. Ray, and K. Richardson. 1995. UK 109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: discovery and antifungal properties, abstr. F70, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
26. Troke, P. F., K. W. Brammer, C. A. Hitchcock, S. Youren, and N. Sarantis. 1995. UK-109,496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidiasis models and early clinical efficacy in oropharyngeal candidiasis (OPC), abstr. F73, p. 125. In Abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.